Osteoporosis Canada - Fracture Liaison Service
  • Home
  • About FLS
    • What is FLS?
    • The Osteoporosis Care Gap
    • OCs Role in Supporting the Implementation of Quality FLSs
    • White Paper: Towards a Fracture-Free Future
  • Canadian FLS Registry
    • FLS Registry Map
    • Osteoporosis Canada FLS Registry Submission
  • Tools & resources
    • FLS Toolkit
    • Essential Elements
    • Key Indicators for Canadian FLSs
    • FLS Information Sheets: The science supporting the FLS model of care
    • Educational resources for healthcare professionals and patients
    • Webinars
    • Join the Canadian FLS Network
  • News
  • Contact Us
  • Search
  • Menu Menu

2019 FLS Comprehensive Audit

2019 FLS Comprehensive Audit

Step 1 of 9

11%
  • Section 1: Information about your FLS

    Within OC’s FLS Registry and for the purposes of this audit, FLSs are assessed by individual hospital sites. For hospital corporations which may operate an FLS at two or more separate sites, a separate submission form must be filled out for each individual FLS site. For any questions in filling out this questionnaire, please contact Luanne Schenkels at lschenkels@osteoporosis.ca
  • FLS site information

Save and continue later by copying this link into a safe place
  • Section 2: Staff working for your FLS

Save and continue later by copying this link into a safe place
  • Section 3: Type of FLS

  • (Click only one answer)
  • (Click only one answer)
  • (Click only one answer)
  • (Click all that apply)
  • (Click all that apply)
  • (Click all that apply)
  • (Click all that apply)
  • If you have clicked on 'f" above, before going any further with this questionnaire...

    ...please provide a brief overview of your program to Luanne Schenkels at Lschenkels@osteoporosis.ca and you will be contacted promptly with guidance for your specific program.
Save and continue later by copying this link into a safe place
  • Section 4: FLS Processes

  • (Click only one answer)
  • (Click only one answer)
  • (Click only one answer)
  • (Click only one answer)
  • (Click only one answer)
  • (Click all that apply)
Save and continue later by copying this link into a safe place
  • Section 5: Annual reporting

  • 10. Annual FLS enrollment reporting:

  • Please list other fracture types (if applicable):
Save and continue later by copying this link into a safe place
  • Section 6: FLS Audit

  • (Click only one answer)
  • A. Hip-only FLS falling under the “no dedicated FLS coordinator” exception rule.

    Please refer to OC’s FLS KPIs v2.0 document for any details regarding the numbers to be reported in this audit. You may access the KPIs by copying this link into your browser: https://fls.osteoporosis.ca/indicator/
  • (Click only one answer)
  • PERSISTENCE: For the purposes of this survey, persistence is defined as documenting that the patient is still on the osteoporosis medication at 52 weeks post fracture. For patients on zoledronic acid, all patients are deemed persistent if they received their last infusion within 12-18 months prior to their 52-week anniversary from their fracture. For patients on denosumab, patients are considered persistent if no more than 7 months has occurred since their last denosumab injection at the 52-week anniversary from their fracture.
  • We are hoping to gather the following: Of the patients listed in A.3., number of patients who are persistent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52 week anniversary from their fracture. And, separately, the number of patients from A.3. where you could not obtain their persistence information at 26 weeks.
  • ADHERENCE: For the purpose of this survey, adherence is defined as those patients who are taking their medication as prescribed by their healthcare provider. This may vary depending on the medication. For oral bisphosphonates (alendronate/risedronate), it is defined as: Taking most of their scheduled doses (e.g. forgetting less than 20% of their scheduled doses) AND also taking their medication in a safe and effective manner (e.g. depending on the oral bisphosphonate, could include taking in the morning, on an empty stomach, etc). • For zoledronic acid, adherence is automatically ensured for 12-18 months following the first dose • For denosumab, remaining faithful with the scheduled doses (i.e. no more than 7 months between doses) • For teriparatide, taking more than 80% of their daily injections.
  • Specifically, we will be looking for the following: Of the patients listed in A.3., number of patients who are both persistent and adherent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52 week anniversary from their fracture. And, separately, provide us the number of patients from A.3. where you could not obtain their adherence information at 26 weeks.
  • B: Inpatient-only FLS (i.e. the FLS coordinator first meets the patient directly on the orthopaedic inpatient ward). Our FLS enrolls only hip fracture patients.

    Please refer to OC’s FLS KPIs v2.0 document for any details regarding the numbers to be reported in this audit. You may access the KPIs by copying this link into your browser: https://fls.osteoporosis.ca/indicator/
  • B.3.a. How many were initiated (or continued) on first-line osteoporosis medication (alendronate, risedronate, zoledronic acid, denosumab or teriparatide) within 26 weeks of their hip fracture?
  • B.3.b. How many were not initiated a first-line osteoporosis medication within 26 weeks of their hip fractures?
  • B.3.c. How many are you not sure if the patient was initiated or not on osteoporosis medication within 26 weeks (e.g. patient lost to follow-up)?
  • (Click only one answer)
  • PERSISTENCE: For the purposes of this survey, persistence is defined as documenting that the patient is still on the osteoporosis medication at 52 weeks post fracture. For patients on zoledronic acid, all patients are deemed persistent if they received their last infusion within 12-18 months prior to their 52-week anniversary from their fracture. For patients on denosumab, patients are considered persistent if no more than 7 months has occurred since their last denosumab injection at the 52-week anniversary from their fracture.
  • Specifically, we will be looking for the following: Of the patients listed in 3a, number of patients who are persistent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52-week anniversary from their fracture. And, separately, provide us the number of patients from 3a where you could not obtain their persistence information at 52 weeks.
  • ADHERENCE: For the purpose of this survey, adherence is defined as those patients who are taking their medication as prescribed by their healthcare provider. This may vary depending on the medication. For oral bisphosphonates (alendronate/risedronate), it is defined as: Taking most of their scheduled doses (e.g. forgetting less than 20% of their scheduled doses) AND also taking their medication in a safe and effective manner (e.g. depending on the oral bisphosphonate, could include taking in the morning, on an empty stomach, etc). • For zoledronic acid, adherence is automatically ensured for 12-18 months following the first dose • For denosumab, remaining faithful with the scheduled doses (i.e. no more than 7 months between doses) • For teriparatide, taking more than 80% of their daily injections.
  • Specifically, we will be looking for the following: Of the patients listed in 3a, number of patients who are both persistent and adherent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52-week anniversary from their fracture. And, separately, provide us the number of patients from 3a where you could not obtain their adherence information at 52 weeks.
  • C: Inpatient-only FLS (i.e. the FLS coordinator first meets the patient directly on the orthopaedic inpatient ward). Our FLS enrolls more than just hip fracture patients.

    Please refer to OC’s FLS KPIs v2.0 document for any details regarding the numbers to be reported in this audit. You may access the KPIs by copying this link into your browser: https://fls.osteoporosis.ca/indicator/
  • a. Hip (proximal femur) fractures
  • b. Wrist (distal radius) fractures
  • c. Shoulder (proximal humerus) fractures
  • d. Pelvic fractures
  • e. Spine/vertebral fractures
  • a. HIGH RISK
  • b. MODERATE RISK
  • c. LOW RISK
  • d. Fracture risk could not be determined within 26 weeks
  • C.4.a. How many were initiated (or continued) on first-line osteoporosis medication (alendronate, risedronate, zoledronic acid, denosumab or teriparatide) within 26 weeks of their fracture?
  • C.4.b. How many were not initiated a first-line osteoporosis medication within 26 weeks of their fractures?
  • C.4.c. How many are you not sure if the patient was initiated or not on osteoporosis medication within 26 weeks (e.g. patient lost to follow-up)?
  • (Click only one answer)
  • PERSISTENCE: For the purposes of this survey, persistence is defined as documenting that the patient is still on the osteoporosis medication at 52 weeks post fracture. For patients on zoledronic acid, all patients are deemed persistent if they received their last infusion within 12-18 months prior to their 52-week anniversary from their fracture. For patients on denosumab, patients are considered persistent if no more than 7 months has occurred since their last denosumab injection at the 52-week anniversary from their fracture.
  • Specifically, we will be looking for the following: Of the patients listed in 3a, number of patients who are persistent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52-week anniversary from their fracture. And, separately, provide us the number of patients from 3a where you could not obtain their persistence information at 52 weeks.
  • ADHERENCE: For the purpose of this survey, adherence is defined as those patients who are taking their medication as prescribed by their healthcare provider. This may vary depending on the medication. For oral bisphosphonates (alendronate/risedronate), it is defined as: Taking most of their scheduled doses (e.g. forgetting less than 20% of their scheduled doses) AND also taking their medication in a safe and effective manner (e.g. depending on the oral bisphosphonate, could include taking in the morning, on an empty stomach, etc). • For zoledronic acid, adherence is automatically ensured for 12-18 months following the first dose • For denosumab, remaining faithful with the scheduled doses (i.e. no more than 7 months between doses) • For teriparatide, taking more than 80% of their daily injections.
  • Can we contact you in December 2019 to request your FLS’s results on adherence? Specifically, we will be looking for the following: Of the patients listed in 3a, number of patients who are both persistent and adherent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52-week anniversary from their fracture. And, separately, provide us the number of patients from 3a where you could not obtain their adherence information at 52 weeks.
  • D: Outpatient-only (i.e. the FLS coordinator first meets the patient directly in the orthopaedic outpatient clinics)

    Please refer to OC’s FLS KPIs v2.0 document for any details regarding the numbers to be reported in this audit. You may access the KPIs by copying this link into your browser: https://fls.osteoporosis.ca/indicator/
  • a. Hip (proximal femur) fractures (within 12 wks)
  • b. Wrist (distal radius) fractures (within 6 wks)
  • c. Shoulder (proximal humerus) fractures (within 6 wks)
  • d. Pelvic fractures (within 6wks)
  • e. Spine/vertebral fractures
  • a. HIGH RISK
  • b. MODERATE RISK
  • c. LOW RISK
  • d. Fracture risk could not be determined within 26 weeks
  • a. How many were initiated (or continued) on first-line osteoporosis medication (alendronate, risedronate, zoledronic acid, denosumab or teriparatide) within 26 weeks of their fracture?
  • b. How many were not initiated a first-line osteoporosis medication within 26 weeks of their fractures?
  • c. How many are you not sure if the patient was initiated or not on osteoporosis medication within 26 weeks (e.g. patient lost to follow-up)?
  • (Click only one answer)
  • PERSISTENCE: For the purposes of this survey, persistence is defined as documenting that the patient is still on the osteoporosis medication at 52 weeks post fracture. For patients on zoledronic acid, all patients are deemed persistent if they received their last infusion within 12-18 months prior to their 52-week anniversary from their fracture. For patients on denosumab, patients are considered persistent if no more than 7 months has occurred since their last denosumab injection at the 52-week anniversary from their fracture.
  • Specifically, we will be looking for the following: Of the patients listed in 3a, number of patients who are persistent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52-week anniversary from their fracture. And, separately, provide us the number of patients from 3a where you could not obtain their persistence information at 52 weeks.
  • ADHERENCE: For the purpose of this survey, adherence is defined as those patients who are taking their medication as prescribed by their healthcare provider. This may vary depending on the medication. • For oral bisphosphonates (alendronate/risedronate), it is defined as: o Taking most of their scheduled doses (e.g. forgetting less than 20% of their scheduled doses) AND o Also taking their medication in a safe and effective manner (e.g. depending on the oral bisphosphonate, could include taking in the morning, on an empty stomach, etc). • For zoledronic acid, adherence is automatically ensured for 12-18 months following the first dose • For denosumab, remaining faithful with the scheduled doses (i.e. no more than 7 months between doses) • For teriparatide, taking more than 80% of their daily injections.
  • Specifically, we will be looking for the following: Of the patients listed in 3a, number of patients who are both persistent and adherent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52-week anniversary from their fracture. And, separately, provide us the number of patients from 3a where you could not obtain their adherence information at 52 weeks.
  • E: Combined inpatient/outpatient FLS (i.e. the FLS coordinator does systematic and pro-active case finding both on the orthopaedic inpatient ward AND in the orthopaedic outpatient clinics).

    Please refer to OC’s FLS KPIs v2.0 document for any details regarding the numbers to be reported in this audit. You may access the KPIs by copying this link into your browser: https://fls.osteoporosis.ca/indicator/
  • a. Hip (proximal femur) fractures (within 12 wks)
  • b. Wrist (distal radius) fractures (within 6 wks)
  • c. Shoulder (proximal humerus) fractures (within 6 wks)
  • d. Pelvic fractures (within 6 wks)
  • e. Spine/vertebral fractures
  • a. HIGH RISK
  • b. MODERATE RISK
  • c. LOW RISK
  • d. Fracture risk could not be determined within 26 weeks
  • a. How many were initiated (or continued) on first-line osteoporosis medication (alendronate, risedronate, zoledronic acid, denosumab or teriparatide) within 26 weeks of their fracture?
  • b. How many were not initiated a first-line osteoporosis medication within 26 weeks of their fractures?
  • c. How many are you not sure if the patient was initiated or not on osteoporosis medication within 26 weeks (e.g. patient lost to follow-up)?
  • (Click only one answer)
  • PERSISTENCE: For the purposes of this survey, persistence is defined as documenting that the patient is still on the osteoporosis medication at 52 weeks post fracture. For patients on zoledronic acid, all patients are deemed persistent if they received their last infusion within 12-18 months prior to their 52-week anniversary from their fracture. For patients on denosumab, patients are considered persistent if no more than 7 months has occurred since their last denosumab injection at the 52-week anniversary from their fracture.
  • Specifically, we will be looking for the following: Of the patients listed in 3a, number of patients who are persistent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52-week anniversary from their fracture. And, separately, provide us the number of patients from 3a where you could not obtain their persistence information at 52 weeks.
  • ADHERENCE: For the purpose of this survey, adherence is defined as those patients who are taking their medication as prescribed by their healthcare provider. This may vary depending on the medication. • For oral bisphosphonates (alendronate/risedronate), it is defined as: o Taking most of their scheduled doses (e.g. forgetting less than 20% of their scheduled doses) AND o Also taking their medication in a safe and effective manner (e.g. depending on the oral bisphosphonate, could include taking in the morning, on an empty stomach, etc). • For zoledronic acid, adherence is automatically ensured for 12-18 months following the first dose • For denosumab, remaining faithful with the scheduled doses (i.e. no more than 7 months between doses) • For teriparatide, taking more than 80% of their daily injections.
  • Specifically, we will be looking for the following: Of the patients listed in 3a, number of patients who are both persistent and adherent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52-week anniversary from their fracture. And, separately, provide us the number of patients from 3a where you could not obtain their adherence information at 52 weeks.
Save and continue later by copying this link into a safe place
  • Section 7: Information on vertebral fractures

  • (Click all that apply)
Save and continue later by copying this link into a safe place
  • Section 8: Resources and Challenges

Save and continue later by copying this link into a safe place
  • Section 9: Permission

  • Osteoporosis Canada may use aggregate data from this audit for possible publication and/or research purposes. The individual FLS sites would remain completely anonymous in the event of any publication.
Save and continue later by copying this link into a safe place

2019 FLS Comprehensive Audit

Step 1 of 9

11%
  • Section 1: Information about your FLS

    Within OC’s FLS Registry and for the purposes of this audit, FLSs are assessed by individual hospital sites. For hospital corporations which may operate an FLS at two or more separate sites, a separate submission form must be filled out for each individual FLS site. For any questions in filling out this questionnaire, please contact Luanne Schenkels at lschenkels@osteoporosis.ca
  • FLS site information

Save and continue later by copying this link into a safe place
  • Section 2: Staff working for your FLS

Save and continue later by copying this link into a safe place
  • Section 3: Type of FLS

  • (Click only one answer)
  • (Click only one answer)
  • (Click only one answer)
  • (Click all that apply)
  • (Click all that apply)
  • (Click all that apply)
  • (Click all that apply)
  • If you have clicked on 'f" above, before going any further with this questionnaire...

    ...please provide a brief overview of your program to Luanne Schenkels at Lschenkels@osteoporosis.ca and you will be contacted promptly with guidance for your specific program.
Save and continue later by copying this link into a safe place
  • Section 4: FLS Processes

  • (Click only one answer)
  • (Click only one answer)
  • (Click only one answer)
  • (Click only one answer)
  • (Click only one answer)
  • (Click all that apply)
Save and continue later by copying this link into a safe place
  • Section 5: Annual reporting

  • 10. Annual FLS enrollment reporting:

  • Please list other fracture types (if applicable):
Save and continue later by copying this link into a safe place
  • Section 6: FLS Audit

  • (Click only one answer)
  • A. Hip-only FLS falling under the “no dedicated FLS coordinator” exception rule.

    Please refer to OC’s FLS KPIs v2.0 document for any details regarding the numbers to be reported in this audit. You may access the KPIs by copying this link into your browser: https://fls.osteoporosis.ca/indicator/
  • (Click only one answer)
  • PERSISTENCE: For the purposes of this survey, persistence is defined as documenting that the patient is still on the osteoporosis medication at 52 weeks post fracture. For patients on zoledronic acid, all patients are deemed persistent if they received their last infusion within 12-18 months prior to their 52-week anniversary from their fracture. For patients on denosumab, patients are considered persistent if no more than 7 months has occurred since their last denosumab injection at the 52-week anniversary from their fracture.
  • We are hoping to gather the following: Of the patients listed in A.3., number of patients who are persistent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52 week anniversary from their fracture. And, separately, the number of patients from A.3. where you could not obtain their persistence information at 26 weeks.
  • ADHERENCE: For the purpose of this survey, adherence is defined as those patients who are taking their medication as prescribed by their healthcare provider. This may vary depending on the medication. For oral bisphosphonates (alendronate/risedronate), it is defined as: Taking most of their scheduled doses (e.g. forgetting less than 20% of their scheduled doses) AND also taking their medication in a safe and effective manner (e.g. depending on the oral bisphosphonate, could include taking in the morning, on an empty stomach, etc). • For zoledronic acid, adherence is automatically ensured for 12-18 months following the first dose • For denosumab, remaining faithful with the scheduled doses (i.e. no more than 7 months between doses) • For teriparatide, taking more than 80% of their daily injections.
  • Specifically, we will be looking for the following: Of the patients listed in A.3., number of patients who are both persistent and adherent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52 week anniversary from their fracture. And, separately, provide us the number of patients from A.3. where you could not obtain their adherence information at 26 weeks.
  • B: Inpatient-only FLS (i.e. the FLS coordinator first meets the patient directly on the orthopaedic inpatient ward). Our FLS enrolls only hip fracture patients.

    Please refer to OC’s FLS KPIs v2.0 document for any details regarding the numbers to be reported in this audit. You may access the KPIs by copying this link into your browser: https://fls.osteoporosis.ca/indicator/
  • B.3.a. How many were initiated (or continued) on first-line osteoporosis medication (alendronate, risedronate, zoledronic acid, denosumab or teriparatide) within 26 weeks of their hip fracture?
  • B.3.b. How many were not initiated a first-line osteoporosis medication within 26 weeks of their hip fractures?
  • B.3.c. How many are you not sure if the patient was initiated or not on osteoporosis medication within 26 weeks (e.g. patient lost to follow-up)?
  • (Click only one answer)
  • PERSISTENCE: For the purposes of this survey, persistence is defined as documenting that the patient is still on the osteoporosis medication at 52 weeks post fracture. For patients on zoledronic acid, all patients are deemed persistent if they received their last infusion within 12-18 months prior to their 52-week anniversary from their fracture. For patients on denosumab, patients are considered persistent if no more than 7 months has occurred since their last denosumab injection at the 52-week anniversary from their fracture.
  • Specifically, we will be looking for the following: Of the patients listed in 3a, number of patients who are persistent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52-week anniversary from their fracture. And, separately, provide us the number of patients from 3a where you could not obtain their persistence information at 52 weeks.
  • ADHERENCE: For the purpose of this survey, adherence is defined as those patients who are taking their medication as prescribed by their healthcare provider. This may vary depending on the medication. For oral bisphosphonates (alendronate/risedronate), it is defined as: Taking most of their scheduled doses (e.g. forgetting less than 20% of their scheduled doses) AND also taking their medication in a safe and effective manner (e.g. depending on the oral bisphosphonate, could include taking in the morning, on an empty stomach, etc). • For zoledronic acid, adherence is automatically ensured for 12-18 months following the first dose • For denosumab, remaining faithful with the scheduled doses (i.e. no more than 7 months between doses) • For teriparatide, taking more than 80% of their daily injections.
  • Specifically, we will be looking for the following: Of the patients listed in 3a, number of patients who are both persistent and adherent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52-week anniversary from their fracture. And, separately, provide us the number of patients from 3a where you could not obtain their adherence information at 52 weeks.
  • C: Inpatient-only FLS (i.e. the FLS coordinator first meets the patient directly on the orthopaedic inpatient ward). Our FLS enrolls more than just hip fracture patients.

    Please refer to OC’s FLS KPIs v2.0 document for any details regarding the numbers to be reported in this audit. You may access the KPIs by copying this link into your browser: https://fls.osteoporosis.ca/indicator/
  • a. Hip (proximal femur) fractures
  • b. Wrist (distal radius) fractures
  • c. Shoulder (proximal humerus) fractures
  • d. Pelvic fractures
  • e. Spine/vertebral fractures
  • a. HIGH RISK
  • b. MODERATE RISK
  • c. LOW RISK
  • d. Fracture risk could not be determined within 26 weeks
  • C.4.a. How many were initiated (or continued) on first-line osteoporosis medication (alendronate, risedronate, zoledronic acid, denosumab or teriparatide) within 26 weeks of their fracture?
  • C.4.b. How many were not initiated a first-line osteoporosis medication within 26 weeks of their fractures?
  • C.4.c. How many are you not sure if the patient was initiated or not on osteoporosis medication within 26 weeks (e.g. patient lost to follow-up)?
  • (Click only one answer)
  • PERSISTENCE: For the purposes of this survey, persistence is defined as documenting that the patient is still on the osteoporosis medication at 52 weeks post fracture. For patients on zoledronic acid, all patients are deemed persistent if they received their last infusion within 12-18 months prior to their 52-week anniversary from their fracture. For patients on denosumab, patients are considered persistent if no more than 7 months has occurred since their last denosumab injection at the 52-week anniversary from their fracture.
  • Specifically, we will be looking for the following: Of the patients listed in 3a, number of patients who are persistent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52-week anniversary from their fracture. And, separately, provide us the number of patients from 3a where you could not obtain their persistence information at 52 weeks.
  • ADHERENCE: For the purpose of this survey, adherence is defined as those patients who are taking their medication as prescribed by their healthcare provider. This may vary depending on the medication. For oral bisphosphonates (alendronate/risedronate), it is defined as: Taking most of their scheduled doses (e.g. forgetting less than 20% of their scheduled doses) AND also taking their medication in a safe and effective manner (e.g. depending on the oral bisphosphonate, could include taking in the morning, on an empty stomach, etc). • For zoledronic acid, adherence is automatically ensured for 12-18 months following the first dose • For denosumab, remaining faithful with the scheduled doses (i.e. no more than 7 months between doses) • For teriparatide, taking more than 80% of their daily injections.
  • Can we contact you in December 2019 to request your FLS’s results on adherence? Specifically, we will be looking for the following: Of the patients listed in 3a, number of patients who are both persistent and adherent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52-week anniversary from their fracture. And, separately, provide us the number of patients from 3a where you could not obtain their adherence information at 52 weeks.
  • D: Outpatient-only (i.e. the FLS coordinator first meets the patient directly in the orthopaedic outpatient clinics)

    Please refer to OC’s FLS KPIs v2.0 document for any details regarding the numbers to be reported in this audit. You may access the KPIs by copying this link into your browser: https://fls.osteoporosis.ca/indicator/
  • a. Hip (proximal femur) fractures (within 12 wks)
  • b. Wrist (distal radius) fractures (within 6 wks)
  • c. Shoulder (proximal humerus) fractures (within 6 wks)
  • d. Pelvic fractures (within 6wks)
  • e. Spine/vertebral fractures
  • a. HIGH RISK
  • b. MODERATE RISK
  • c. LOW RISK
  • d. Fracture risk could not be determined within 26 weeks
  • a. How many were initiated (or continued) on first-line osteoporosis medication (alendronate, risedronate, zoledronic acid, denosumab or teriparatide) within 26 weeks of their fracture?
  • b. How many were not initiated a first-line osteoporosis medication within 26 weeks of their fractures?
  • c. How many are you not sure if the patient was initiated or not on osteoporosis medication within 26 weeks (e.g. patient lost to follow-up)?
  • (Click only one answer)
  • PERSISTENCE: For the purposes of this survey, persistence is defined as documenting that the patient is still on the osteoporosis medication at 52 weeks post fracture. For patients on zoledronic acid, all patients are deemed persistent if they received their last infusion within 12-18 months prior to their 52-week anniversary from their fracture. For patients on denosumab, patients are considered persistent if no more than 7 months has occurred since their last denosumab injection at the 52-week anniversary from their fracture.
  • Specifically, we will be looking for the following: Of the patients listed in 3a, number of patients who are persistent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52-week anniversary from their fracture. And, separately, provide us the number of patients from 3a where you could not obtain their persistence information at 52 weeks.
  • ADHERENCE: For the purpose of this survey, adherence is defined as those patients who are taking their medication as prescribed by their healthcare provider. This may vary depending on the medication. • For oral bisphosphonates (alendronate/risedronate), it is defined as: o Taking most of their scheduled doses (e.g. forgetting less than 20% of their scheduled doses) AND o Also taking their medication in a safe and effective manner (e.g. depending on the oral bisphosphonate, could include taking in the morning, on an empty stomach, etc). • For zoledronic acid, adherence is automatically ensured for 12-18 months following the first dose • For denosumab, remaining faithful with the scheduled doses (i.e. no more than 7 months between doses) • For teriparatide, taking more than 80% of their daily injections.
  • Specifically, we will be looking for the following: Of the patients listed in 3a, number of patients who are both persistent and adherent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52-week anniversary from their fracture. And, separately, provide us the number of patients from 3a where you could not obtain their adherence information at 52 weeks.
  • E: Combined inpatient/outpatient FLS (i.e. the FLS coordinator does systematic and pro-active case finding both on the orthopaedic inpatient ward AND in the orthopaedic outpatient clinics).

    Please refer to OC’s FLS KPIs v2.0 document for any details regarding the numbers to be reported in this audit. You may access the KPIs by copying this link into your browser: https://fls.osteoporosis.ca/indicator/
  • a. Hip (proximal femur) fractures (within 12 wks)
  • b. Wrist (distal radius) fractures (within 6 wks)
  • c. Shoulder (proximal humerus) fractures (within 6 wks)
  • d. Pelvic fractures (within 6 wks)
  • e. Spine/vertebral fractures
  • a. HIGH RISK
  • b. MODERATE RISK
  • c. LOW RISK
  • d. Fracture risk could not be determined within 26 weeks
  • a. How many were initiated (or continued) on first-line osteoporosis medication (alendronate, risedronate, zoledronic acid, denosumab or teriparatide) within 26 weeks of their fracture?
  • b. How many were not initiated a first-line osteoporosis medication within 26 weeks of their fractures?
  • c. How many are you not sure if the patient was initiated or not on osteoporosis medication within 26 weeks (e.g. patient lost to follow-up)?
  • (Click only one answer)
  • PERSISTENCE: For the purposes of this survey, persistence is defined as documenting that the patient is still on the osteoporosis medication at 52 weeks post fracture. For patients on zoledronic acid, all patients are deemed persistent if they received their last infusion within 12-18 months prior to their 52-week anniversary from their fracture. For patients on denosumab, patients are considered persistent if no more than 7 months has occurred since their last denosumab injection at the 52-week anniversary from their fracture.
  • Specifically, we will be looking for the following: Of the patients listed in 3a, number of patients who are persistent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52-week anniversary from their fracture. And, separately, provide us the number of patients from 3a where you could not obtain their persistence information at 52 weeks.
  • ADHERENCE: For the purpose of this survey, adherence is defined as those patients who are taking their medication as prescribed by their healthcare provider. This may vary depending on the medication. • For oral bisphosphonates (alendronate/risedronate), it is defined as: o Taking most of their scheduled doses (e.g. forgetting less than 20% of their scheduled doses) AND o Also taking their medication in a safe and effective manner (e.g. depending on the oral bisphosphonate, could include taking in the morning, on an empty stomach, etc). • For zoledronic acid, adherence is automatically ensured for 12-18 months following the first dose • For denosumab, remaining faithful with the scheduled doses (i.e. no more than 7 months between doses) • For teriparatide, taking more than 80% of their daily injections.
  • Specifically, we will be looking for the following: Of the patients listed in 3a, number of patients who are both persistent and adherent with first-line osteoporosis medication (include patients who are either still on same medication or switched to another medication) at the 52-week anniversary from their fracture. And, separately, provide us the number of patients from 3a where you could not obtain their adherence information at 52 weeks.
Save and continue later by copying this link into a safe place
  • Section 7: Information on vertebral fractures

  • (Click all that apply)
Save and continue later by copying this link into a safe place
  • Section 8: Resources and Challenges

Save and continue later by copying this link into a safe place
  • Section 9: Permission

  • Osteoporosis Canada may use aggregate data from this audit for possible publication and/or research purposes. The individual FLS sites would remain completely anonymous in the event of any publication.
Save and continue later by copying this link into a safe place

© Copyright - Osteoporosis Canada - Fracture Liaison Service | Privacy Policy
Scroll to top